BACKGROUND: GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-
glucose cotransporter 2) inhibitors both improve cardiovascular and kidney outcomes in …

Background SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and
kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the …

Summary Background The EMPA-KIDNEY trial showed that empagliflozin reduced the risk
of the primary composite outcome of kidney disease progression or cardiovascular death in …

While lifestyle changes such as dietary modification and increased physical activity can be
very effective in improving glycemic control, over the long-term most individuals with Type 2 …

Background Empagliflozin exerted positive cardiorenal effects in the EMPA-KIDNEY trial;
this study reports active trial plus post-trial data. Methods In this trial, patients with an …

Abstract Background In the EMPA-KIDNEY trial, empagliflozin, a sodium–glucose
cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic …

Chronic kidney disease is common and is associated with an increased risk of
cardiovascular disease and progression to kidney failure. It has many causes, of which …

Abstract Background The Kidney Disease Improving Global Outcomes (KDIGO)
classification integrates both estimated glomerular filtration rate and urine-albumin …

Background: This systematic review and meta-analysis aimed to evaluate the efficacy and
safety of novel antidiabetics, namely, sodium-glucose transport protein 2 inhibitors (SGLT2-i) …

Chronic kidney disease (CKD) affects approximately 13% of people globally, including 20%–
48% with type 2 diabetes (T2D), resulting in significant morbidity, mortality, and healthcare …